Today the first subscription period for TO1 commences

Genom de teckningsoptioner av serie TO 1 som emitterades i samband med note­ringsemissionen i april 2015 kan aktier tecknas under perioden 12 oktober –  21 oktober 2015 och/eller den 8 februari – 17 februari 2016. En teckningsoption av serie TO 1 berättigar till teckning av en aktie för sju kronor och femtio öre (7,50). Idag inleds den första teckningsperioden.
Läs mer >>
Ladda ner anmälningssedel >>

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Agavägen 52A, SE-181 55 Lidingö

 

Linked In     Twitter      Facebook